- Home
- DBVT vs GROV Comparison
DBVT vs GROV Comparison
Compare DBVT & GROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- GROV
- Stock Information
- Founded
- DBVT 2002
- GROV 2016
- Country
- DBVT France
- GROV United States
- Employees
- DBVT N/A
- GROV N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- GROV Package Goods/Cosmetics
- Sector
- DBVT Health Care
- GROV Consumer Discretionary
- Exchange
- DBVT Nasdaq
- GROV Nasdaq
- Market Cap
- DBVT 67.8M
- GROV 56.5M
- IPO Year
- DBVT N/A
- GROV N/A
- Fundamental
- Price
- DBVT $0.59
- GROV $1.30
- Analyst Decision
- DBVT Strong Buy
- GROV Buy
- Analyst Count
- DBVT 2
- GROV 1
- Target Price
- DBVT $6.00
- GROV $2.00
- AVG Volume (30 Days)
- DBVT 2.0M
- GROV 85.8K
- Earning Date
- DBVT 11-06-2024
- GROV 11-12-2024
- Dividend Yield
- DBVT N/A
- GROV N/A
- EPS Growth
- DBVT N/A
- GROV N/A
- EPS
- DBVT N/A
- GROV N/A
- Revenue
- DBVT $12,515,000.00
- GROV $213,781,000.00
- Revenue This Year
- DBVT N/A
- GROV N/A
- Revenue Next Year
- DBVT $2,860.00
- GROV $5.97
- P/E Ratio
- DBVT N/A
- GROV N/A
- Revenue Growth
- DBVT 125.54
- GROV N/A
- 52 Week Low
- DBVT $0.50
- GROV $1.19
- 52 Week High
- DBVT $2.14
- GROV $2.49
- Technical
- Relative Strength Index (RSI)
- DBVT 34.55
- GROV 45.78
- Support Level
- DBVT $0.56
- GROV $1.31
- Resistance Level
- DBVT $0.81
- GROV $1.46
- Average True Range (ATR)
- DBVT 0.05
- GROV 0.09
- MACD
- DBVT -0.02
- GROV 0.00
- Stochastic Oscillator
- DBVT 10.42
- GROV 22.58
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.